Northstar Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Northstar Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,714	Closed	-$591K	–	192
2018 Q2	$591K	Sell	1,714 -140	-8%	-$43.8K	0.3%	98
2018 Q1	$638K	Sell	1,854 -27	-1%	-$9.39K	0.33%	94
2017 Q4	$701K	Buy	1,881 +9	+0.5%	+$3.65K	0.62%	54
2017 Q3	$879K	Sell	1,872 -500	-21%	-$238K	0.86%	39
2017 Q2	$1.19M	Sell	2,372 -802	-25%	-$351K	1.08%	26
2017 Q1	$1.2M	Buy	+3,174	New	+$1.18M	1.11%	26

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northstar Wealth Partners's REGN Position: Q3 2018 in Review

Northstar Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 1,714 shares — an estimated $591K sold.

Northstar Wealth Partners first reported a position in REGN in Q1 2017 and held it in 6 quarters. The position peaked at $1.2M in Q1 2017. 645 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Northstar Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Northstar Wealth Partners sold 1,714 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $591K.
Northstar Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Northstar Wealth Partners's Regeneron Pharmaceuticals position peaked at $1.2M in Q1 2017.
645 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Northstar Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.